Methods and compositions for treating bacterial infection

1. A pharmaceutical composition, comprising:

a compound selected from the group consisting of a)

Wherein X is S, NH, or O, R 1 and R 2 are, independently, selected from the group consisting of a C1-C8 alkyl, a C1-C8 alkenyl, and a C1-C8 cycloalkyl, wherein said C1-C8 alkyl, a C1-C8 alkenyl, and a C1-C8 cycloalkyl are optionally substituted with F, CN, OR 6 , NR 6 2 , COR 6 , CO 2 R 6 , CONHR 6 , aryl or heteroaryl, wherein one or more alkyl carbons may be replaced by O;

R 3 and R 4 are joined in a cycloalkyl ring of 3-7 carbons wherein at least one ring CH 2 is replaced by 0 or N-G;

G is selected from the group consisting of H, C(═O)R 6 , SO 2 R 6 and C(═O)OR 6 ;

R 5 is selected from the group consisting of H, C1-C6 alkyl, CN, OR 6 , NR 6 2 , COR 6 , CO 2 R 6 , CONHR 6 , aryl, heteroaryl, SO 2 R 6 , NHCOR 6 , SO 2 NHR 6 , and OCOR 6 ;

R 6 is selected from the group consisting of H, C1-C6 alkyl, C0-C3 alkyl-aryl, and C0-C3 alkyl-heteroaryl, all optionally substituted; and

R 11 is H or a C1 alkyl;

b) a compound having the structure

Wherein X is S, R 1 is a C-C8 alkyl substituted with at least one F, R 2 is selected from the group consisting of a C1-C8 alkyl, a C1-C8 alkenyl, and a C1-C8 cycloalkyl, wherein said C1-C8 alkyl, a C1-C8 alkenyl, and a C1-C8 cycloalkyl are optionally substituted with F, CN, OR 6 , NR 6 2 , COR 6 , CO 2 R 6 , CONHR 6 , aryl or heteroaryl, wherein one or more alkyl carbons may be replaced by O;

R 3 and R 4 are independently a C1-C8 alkyl, H, or joined in a cycloalkyl ring of 3-7 carbons wherein at least one ring CH 2 is replaced by O or N-G;

G is selected from the group consisting of H, C(═O)R 6 , SO 2 R 6 and C(═O)OR 6 ;

R 5 is selected from the group consisting of H, C1-C6 alkyl, CN, OR 6 , NR 6 2 , COR 6 , CO 2 R 6 , CONHR 6 , aryl, heteroaryl, SO 2 R 6 , NHCOR 6 , SO 2 NHR 6 , and OCOR 6 ;

R 6 is selected from the group consisting of H, C1-C6 alkyl, C0-C3 alkyl-aryl, and C0-C3 alkyl-heteroaryl, all optionally substituted; and

R 11 is H or a C1 alkyl; and

c) a compound having the structure:

Wherein R 1 and R 2 are, independently, selected from the group consisting of a C1-C8 alkyl, a C1-C8 alkenyl, and a C1-C8 cycloalkyl, wherein said C1-C8 alkyl, a C1-C8 alkenyl, and a C1-C8 cycloalkyl are optionally substituted with F, CN, OR 6 , NR 6 2 , COR 6 , CO 2 R 6 , CONHR 6 , aryl or heteroaryl, wherein one or more alkyl carbons may be replaced by O;

R 5 is selected from the group consisting of H, C1-C6 alkyl, CN, OR 6 , NR 6 2 , COR 6 , CO 2 R 6 , CONHR 6 , aryl, heteroaryl, SO 2 R 6 , NHCOR 6 , SO 2 NHR 6 , and OCOR 6 ;

R 6 is selected from the group consisting of H, C1-C6 alkyl, C0-C3 alkyl-aryl, and C0-C3 alkyl-heteroaryl, all optionally substituted;

R 7 and R 8 are independently selected from the group consisting of H, C1-C6 alkyl, and joined in a cycloalkyl ring of 3-7 carbons, wherein one of the ring CH 2 groups may be replaced by O or N-G;

R 9 is a C1-C5 alkyl; and

R 10 is a C2-C8 alkyl or alkenyl or cycloalkyl, optionally substituted with F, CN, OR 6 , NR 6 2 , CO 2 R 6 , CONHR 6 , aryl or heteroaryl, wherein one or more alkyl carbons may be replaced by O.

2. The composition of claim 1 , wherein said compound is selected from the group consisting of:

3. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

4. The composition of claim 1 , wherein said composition inhibits growth or biological activity of S. aureus and/or S. epidermidis.

5. The composition of claim 1 , wherein said composition inhibits biofilm formation by S. aureus and/or S. epidermidis.

6. The composition of claim 4 , wherein said S. aureus and/or S. epidermidis are in a biofilm.

7. The composition of claim 1 , wherein said composition further comprises a known antibiotic compound.

8. A method of inhibiting the growth or biological activity of S. aureus and/or S. epidermidis , comprising contacting said S. aureus and/or S. epidermidis with a compound having the structure of Formula I, II, III or IV

Wherein X is S, NH, or O, R 1 and R 2 are, independently, selected from the group consisting of a C1-C8 alkyl, a C1-C8 alkenyl, and a C1-C8 cycloalkyl, wherein said C1-C8 alkyl, a C1-C8 alkenyl, and a C1-C8 cycloalkyl are optionally substituted with F, CN, OR 6 , NR 6 2 , COR 6 , CO 2 R 6 , CONHR 6 , aryl or heteroaryl, wherein one or more alkyl carbons may be replaced by O;

R 3 and R 4 are independently H, a C1-C8 alkyl, or joined in a cycloalkyl ring of 3-7 carbons wherein at least one ring CH 2 is replaced by O or N-G;

G is selected from the group consisting of H, C(═O)R 6 , SO 2 R 6 and C(═O)OR 6 ;

R 5 is selected from the group consisting of H, C1-C6 alkyl, CN, OR 6 , NR 6 2 , COR 6 , CO 2 R 6 , CONHR 6 , aryl, heteroaryl, SO 2 R 6 , NHCOR 6 , SO 2 NHR 6 , and OCOR 6 ;

R 6 is selected from the group consisting of H, C1-C6 alkyl, C0-C3 alkyl-aryl, and C0-C3 alkyl-heteroaryl, all optionally substituted;

R 7 and R 8 are independently selected from the group consisting of H, C1-C6 alkyl, and joined in a cycloalkyl ring of 3-7 carbons, wherein one of the ring CH 2 groups may be replaced by O or N-G;

R 9 is a C1-C5 alkyl;

R 10 is a C2-C8 alkyl or alkenyl or cycloalkyl, optionally substituted with F, CN, OR 6 , NR 6 2 , CO 2 R 6 , CONHR 6 , aryl or heteroaryl, wherein one or more alkyl carbons may be replaced by O; and

R 11 is H or a C1 alkyl,

wherein said compound inhibits the growth or biological activity of said S. aureus and/or S. epidermidis.

9. The method of claim 8 , wherein said S. aureus and/or S. epidermidis are present in a biofilm.

10. The method of claim 9 , wherein said compound prevents biofilm formation by said S. aureus and/or S. epidermidis.

11. The method of claim 8 , further comprising the step of contacting said S. aureus and/or S. epidermidis with a known antibiotic compound.

12. A surface coated in a compound of claim 1 .

13. The surface of claim 12 , wherein said surface is a surface of a medical device.